Meishealth: Wins 21 million RMB project bid.

Mes Health Announcement: Recently, our subsidiary Shanghai Mes Medicine Technology Co., Ltd. has won a large real-world research project from a pharmaceutical company in China. The project aims to "systematically evaluate the effectiveness and safety of IL-1 monoclonal antibody treatment for patients with acute and intermittent gout through a combination of prospective and retrospective observational studies." The project is worth approximately 21 million RMB.